Interim report January – March 2022
The period in summary
First quarter January 1 – March 31, 2022
– On March 23 the first batch of Strangvac was released for sale in Sweden.
– Intervacc has applied for supplementary protection certificates (SPCs) for Strangvac in key European markets. SPCs are an intellectual property right that serves as an extension to a patent right.
– EMA extended the shelf life of the antigens used in Strangvac to 28 months.
– During February an application for a Permit for Sale and Distribution of Strangvac in the U.S. was submitted to the U.S. Department of